The Uncertain Path Forward for Psychedelic Medicine
by Emily Mullin from Feed: All Latest on (#6Q0NT)
After the FDA rejected its proposed MDMA treatment, Lykos Therapeutics is laying off 75 percent of its staff and its founder has left the company.